ReviewJournal of personalized medicine2021
A Systematic Review on the Contribution of Artificial Intelligence in the Development of Medicines for COVID-2019.
Review in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 23 citations in OpenAlex.
- An overview of reviews on digital health interventions during COVID- 19 era: insights and lessons for future pandemics.Archives of public health = Archives belges de sante publique · 2025Article
- Artificial Intelligence-Assisted Comparative Analysis of the Overlapping Molecular Pathophysiology of Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia.International journal of molecular sciences · 2024Article
- Cross-Domain Text Mining of Pathophysiological Processes Associated with Diabetic Kidney Disease.International journal of molecular sciences · 2024Article
- Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19.Biology · 2023Article
- Literature-Based Discovery Predicts Antihistamines Are a Promising Repurposed Adjuvant Therapy for Parkinson's Disease.International journal of molecular sciences · 2023Article
- Artificial Intelligence Technologies for COVID-19 De Novo Drug Design.International journal of molecular sciences · 2022Review
- Can anti-parasitic drugs help control COVID-19?Future virology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID-2019 pandemic lead to a raised interest on the development of new treatments through Artificial Intelligence (AI).
aimto carry out a systematic review on the development of repurposed drugs against COVID-2019 through the application of AI.
methodsThe Systematic Reviews and Meta-Analyses (PRISMA) checklist was applied. KEYWORDS: ["Artificial intelligence" and (COVID or SARS) and (medicine or drug)]. Databases: PubMed
resultsFrom the 277 identified records [PubMed
conclusionDiverse potentially repurposed drugs against COVID-2019 were identified. The repurposed drugs were mainly from antivirals, antibiotics, anticancer, anti-inflammatory, and Angiotensin-converting enzyme 2 (ACE2) groups, although diverse other pharmacologic groups were covered. AI was a suitable tool to quickly analyze large amounts of data or to estimate drug repurposing against COVID-2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.